SAB BIOTHERAPEUTICS, INC. Increase (Decrease) in Accrued Interest Receivable, Net
SAB BIOTHERAPEUTICS, INC. (SABS) reported Increase (Decrease) in Accrued Interest Receivable, Net of $897.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2026-06-30 was $288.72K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2026-03-31 was $608.28K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2025-12-31 was $386.83K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2025-09-30 was $560.00K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2025 was $891.83K, a 1522.83% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2024 was $54.95K.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month | Increase (Decrease) in Accrued Interest Receivable, Net 6 month | Increase (Decrease) in Accrued Interest Receivable, Net 6 month as first filed | Increase (Decrease) in Accrued Interest Receivable, Net 9 month | Increase (Decrease) in Accrued Interest Receivable, Net 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $288.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $897.00K 10-Q · filed 2026-08-06 | $1.28M derived: sum of 3 quarters · filed 2026-08-06 | $1.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $608.28K 10-Q · filed 2026-05-12 | $995.11K derived: sum of 2 quarters · filed 2026-05-12 | $1.56M derived: sum of 3 quarters · filed 2026-05-12 | $1.53M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $386.83K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $946.83K derived: sum of 2 quarters · filed 2026-03-09 | $925.39K derived: sum of 3 quarters · filed 2026-08-06 | $891.83K 10-K · filed 2026-03-09 | |
| 2025-09-30 | $560.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $538.57K derived: sum of 2 quarters · filed 2026-08-06 | $505.00K 10-Q · filed 2025-11-14 | $462.91K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$21.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$55.00K 10-Q · filed 2026-08-06 | -$54.95K 10-Q · filed 2025-08-07 | -$97.09K derived: sum of 3 quarters · filed 2026-08-06 | -$224.97K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$33.57K 10-Q · filed 2026-05-12 | -$75.66K derived: sum of 2 quarters · filed 2026-05-12 | -$203.54K derived: sum of 3 quarters · filed 2026-05-12 | -$171.85K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$42.09K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$169.97K derived: sum of 2 quarters · filed 2026-03-09 | -$138.28K derived: sum of 3 quarters · filed 2026-03-09 | $54.95K 10-K · filed 2026-03-09 | |
| 2024-09-30 | -$127.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$96.19K derived: sum of 2 quarters · filed 2025-11-14 | $97.05K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $31.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $224.92K 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $193.23K 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |